Kalaris Therapeutics (KLRS) Stock Price, News & Analysis

Company Overview

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Key Stats

• Today's Range: $2.55 to $2.67
• 50-Day Range: N/A
• 52-Week Range: $2.45 to $24.15
• Volume: 36,260 shs
• Average Volume: 39,565 shs
• Market Capitalization: $48.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

KLRS Stock Analysis - Frequently Asked Questions

How have KLRS shares performed this year?

Kalaris Therapeutics' stock was trading at $2.79 at the beginning of 2025. Since then, KLRS stock has decreased by 7.9% and is now trading at $2.57.
View the best growth stocks for 2025 here.

How do I buy shares of Kalaris Therapeutics?

Shares of KLRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 6/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KLRS
• CIK: 1754068
• Web: N/A
• Phone: (617) 433-2605
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$58.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -62.08%
• Return on Assets: -54.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.31
• Quick Ratio: 14.31

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $22.47 per share
• Price / Book: 0.11

Miscellaneous

• Outstanding Shares: 18,700,000
• Free Float: 12,704,000
• Market Cap: $48.06 million
• Optionable: N/A
• Beta: 0.49